These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 30779243

  • 1. Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.
    Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Borén J.
    J Intern Med; 2019 May; 285(5):562-577. PubMed ID: 30779243
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.
    Björnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Söderlund S, Kahri J, Hakkarainen A, Lundbom N, Lundbom J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Borén J.
    J Intern Med; 2020 Oct; 288(4):422-438. PubMed ID: 31846520
    [Abstract] [Full Text] [Related]

  • 3. Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes.
    Taskinen MR, Björnson E, Kahri J, Söderlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Borén J.
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):962-975. PubMed ID: 33356392
    [Abstract] [Full Text] [Related]

  • 4. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity.
    Adiels M, Matikainen N, Westerbacka J, Söderlund S, Larsson T, Olofsson SO, Borén J, Taskinen MR.
    Atherosclerosis; 2012 May; 222(1):222-8. PubMed ID: 22365426
    [Abstract] [Full Text] [Related]

  • 5. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
    Taskinen MR, Björnson E, Matikainen N, Söderlund S, Pietiläinen KH, Ainola M, Hakkarainen A, Lundbom N, Fuchs J, Thorsell A, Andersson L, Adiels M, Packard CJ, Borén J.
    Diabetes Obes Metab; 2021 May; 23(5):1191-1201. PubMed ID: 33502078
    [Abstract] [Full Text] [Related]

  • 6. Hypothesis II: The majority of VLDL-apoB48 remnants in postprandial plasma are derived from the liver, not from the intestine.
    Nakajima K, Tokita Y, Tanaka A.
    Clin Chim Acta; 2019 Mar; 490():12-16. PubMed ID: 30553860
    [Abstract] [Full Text] [Related]

  • 7. Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.
    Taskinen MR, Björnson E, Matikainen N, Söderlund S, Rämö J, Ainola MM, Hakkarainen A, Sihlbom C, Thorsell A, Andersson L, Bergh PO, Henricsson M, Romeo S, Adiels M, Ripatti S, Laakso M, Packard CJ, Borén J.
    JCI Insight; 2022 Oct 10; 7(19):. PubMed ID: 36040803
    [Abstract] [Full Text] [Related]

  • 8. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy.
    Taskinen MR, Matikainen N, Björnson E, Söderlund S, Inkeri J, Hakkarainen A, Parviainen H, Sihlbom C, Thorsell A, Andersson L, Adiels M, Packard CJ, Borén J.
    Diabetologia; 2023 Dec 10; 66(12):2307-2319. PubMed ID: 37775612
    [Abstract] [Full Text] [Related]

  • 9. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
    Borén J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, Ståhlman M, Ripatti P, Ripatti S, Palotie A, Mancina RM, Hakkarainen A, Romeo S, Packard CJ, Taskinen MR.
    JCI Insight; 2020 Dec 17; 5(24):. PubMed ID: 33170809
    [Abstract] [Full Text] [Related]

  • 10. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis.
    Olofsson SO, Borèn J.
    J Intern Med; 2005 Nov 17; 258(5):395-410. PubMed ID: 16238675
    [Abstract] [Full Text] [Related]

  • 11. Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia.
    Ferchaud-Roucher V, Zair Y, Aguesse A, Krempf M, Ouguerram K.
    J Clin Endocrinol Metab; 2020 Oct 01; 105(10):. PubMed ID: 32805740
    [Abstract] [Full Text] [Related]

  • 12. Model development to describe the heterogeneous kinetics of apolipoprotein B and triglyceride in hypertriglyceridemic subjects.
    Barrett PH, Baker N, Nestel PJ.
    J Lipid Res; 1991 May 01; 32(5):743-62. PubMed ID: 2072038
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Apolipoprotein B48, the Structural Component of Chylomicrons, Is Sufficient to Antagonize Staphylococcus aureus Quorum-Sensing.
    Elmore BO, Triplett KD, Hall PR.
    PLoS One; 2015 May 01; 10(5):e0125027. PubMed ID: 25942561
    [Abstract] [Full Text] [Related]

  • 15. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
    Matikainen N, Björnson E, Söderlund S, Borén C, Eliasson B, Pietiläinen KH, Bogl LH, Hakkarainen A, Lundbom N, Rivellese A, Riccardi G, Després JP, Alméras N, Holst JJ, Deacon CF, Borén J, Taskinen MR.
    PLoS One; 2016 May 01; 11(1):e0145890. PubMed ID: 26752550
    [Abstract] [Full Text] [Related]

  • 16. Metabolic basis of hypotriglyceridemic effects of insulin in normal men.
    Malmström R, Packard CJ, Watson TD, Rannikko S, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR.
    Arterioscler Thromb Vasc Biol; 1997 Jul 01; 17(7):1454-64. PubMed ID: 9261280
    [Abstract] [Full Text] [Related]

  • 17. Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes.
    Johansen RF, Søndergaard E, Sørensen LP, Jurik AG, Christiansen JS, Nielsen S.
    Diabetologia; 2016 Apr 01; 59(4):833-43. PubMed ID: 26781548
    [Abstract] [Full Text] [Related]

  • 18. Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects.
    Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Järvinen H, Shepherd J, Taskinen MR.
    Diabetes; 1998 May 01; 47(5):779-87. PubMed ID: 9588450
    [Abstract] [Full Text] [Related]

  • 19. In vivo studies of VLDL metabolism and LDL heterogeneity.
    Demant T, Packard C.
    Eur Heart J; 1998 Jul 01; 19 Suppl H():H7-10. PubMed ID: 9717058
    [Abstract] [Full Text] [Related]

  • 20. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients.
    Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, Pacini G, Rizzetto M, Pagano G.
    Lipids; 2001 Oct 01; 36(10):1117-24. PubMed ID: 11768156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.